Synlogic Inc (SYBX)

Trade SYBX now with
1/19/2023 7:10:35 AM Synlogic Gets Rare Pediatric Disease Designation From FDA For SYNB1934 For Phenylketonuria
8/23/2022 7:26:34 AM Synlogic Says FDA Grants Fast Track Designation For SYNB1353 For Treatment Of Homocystinuria
8/11/2022 7:10:48 AM Synlogic Announces Partnership With Ginkgo Bioworks For The Treatment Of Gout
3/17/2022 7:23:35 AM Synlogic Q4 Net Loss $15.1 Mln Or $0.21/shr Vs Loss Of $14.6 Mln Or $0.39/Shr Last Year
3/3/2022 7:13:51 AM Synlogic Names Michael Jensen As CFO
11/22/2021 8:01:11 PM Synlogic :Data Shows Reductions In Plasma Phenylalanine Levels In Patients With Phenylketonuria Treated With SYNB1618
11/10/2021 7:11:03 AM Synlogic Q3 Consolidated Net Loss $16.0 Mln Vs. Net Loss $13.2 Mln Last Year
9/27/2021 6:32:07 AM Synlogic Appoints Molly Harper As Chief Business Officer
9/22/2021 11:44:11 PM Synlogic Prices Public Offering Of 15 Mln Shares At $3/Shr
9/20/2021 6:33:14 AM Synlogic Announces Positive Phase 2 Data Evaluating Both SYNB1618 And SYNB1934 For Phenylketonuria
9/10/2021 10:32:17 AM Synlogic Presents Data On SYNB8802 For Enteric Hyperoxaluria At American Urological Association Annual Meeting
8/12/2021 6:34:05 AM Synlogic Q2 Net $14.5 Mln Vs. Net Loss $15.5 Mln Last Year
7/15/2021 6:33:59 AM Synlogic Begins Phase 1 Study Of SYNB1934 For Phenylketonuria
6/17/2021 7:39:45 AM Synlogic Enters Research Collaboration Agreement With Roche
5/13/2021 6:40:42 AM Synlogic Q1 Consolidated Net Loss $15.0 Mln Or $0.36/Shr Vs Loss $15.8 Mln Or $0.46/Shr Last Year